Literature DB >> 12240908

Benzodiazepines and anterior pituitary function.

E Arvat1, R Giordano, S Grottoli, E Ghigo.   

Abstract

Benzodiazepines (BDZ) are one of the most prescribed classes of drugs because of their marked anxiolytic, anticonvulsant, muscle relaxant and hypnotic effects. The pharmacological actions of BDZ depend on the activation of 2 specific receptors. The central BDZ receptor, present in several areas of the central nervous system (CNS), is a component of the GABA-A receptor, the activation of which increases GABAergic neurotransmission and is followed by remarkable neuroendocrine effects. The peripheral benzodiazepine receptors (PBR), structurally and functionally different from the GABA-A receptor, have been shown in peripheral tissues but also in the CNS, in both neurones and glial cells, and in the pituitary gland. BDZ receptors bind to a family of natural peptides called endozepines, firstly isolated from neurons and glial cells in the brain and then in several peripheral tissues as well. Endozepines modulate several central and peripheral biological activities, including some neuroendocrine functions and synthetic BDZ are likely to mimic them, at least partially. BZD, especially alprazolam (AL), possess a clear inhibitory influence on the activity of the HPA axis in both animals and humans. This effect seems to be mediated at the hypothalamic and/or suprahypothalamic level via suppression of CRH. The strong negative influence of AL on hypothalamicpituitary-adrenal (HPA) axis agrees with its peculiar efficacy in the treatment of panic disorders and depression. BZD have also been shown to increase GH secretion via mechanisms mediated at the hypothalamic or supra-hypothalamic level, though a pituitary action cannot be ruled out. Besides the impact on HPA and somatotrope function, BDZ also significantly affect the secretion of other pituitary hormones, such as gonadotropins and PRL, probably acting through GABAergic mediation in the hypothalamus and/or in the pituitary gland. In all, BDZ are likely to represent a useful tool to investigate GABAergic activity and clarify its role in the neuroendocrine control of anterior pituitary function; their usefulness probably overrides what had been supposed before.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12240908     DOI: 10.1007/BF03345110

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  131 in total

1.  Is inhibition by diazepam and beta-carbolines of estrogen-induced luteinizing hormone secretion related to sedative effects?

Authors:  P A Gargiulo; A O Donoso
Journal:  Pharmacol Biochem Behav       Date:  1991-10       Impact factor: 3.533

2.  Corticotropin releasing factor produces behavioural activation in rats.

Authors:  R E Sutton; G F Koob; M Le Moal; J Rivier; W Vale
Journal:  Nature       Date:  1982-05-27       Impact factor: 49.962

3.  Reduction in urinary free cortisol during benzodiazepine treatment of panic disorder.

Authors:  A L Lopez; R G Kathol; R Noyes
Journal:  Psychoneuroendocrinology       Date:  1990       Impact factor: 4.905

Review 4.  Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression.

Authors:  G W Dawson; S G Jue; R N Brogden
Journal:  Drugs       Date:  1984-02       Impact factor: 9.546

5.  The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans.

Authors:  S Grottoli; R Giordano; B Maccagno; M Pellegrino; E Ghigo; E Arvat
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

6.  Alprazolam blocks the naloxone-stimulated hypothalamo-pituitary-adrenal axis in man.

Authors:  D J Torpy; J E Grice; G I Hockings; M M Walters; G V Crosbie; R V Jackson
Journal:  J Clin Endocrinol Metab       Date:  1993-02       Impact factor: 5.958

7.  Comparison of alprazolam, imipramine, and placebo in the treatment of depression.

Authors:  J P Feighner; G C Aden; L F Fabre; K Rickels; W T Smith
Journal:  JAMA       Date:  1983-06-10       Impact factor: 56.272

8.  Effect of bromazepam on growth hormone and prolactin secretion in normal subjects.

Authors:  M D'Armiento; G Bisignani; G Reda
Journal:  Horm Res       Date:  1981

9.  Effects of dexamethasone and alprazolam, a benzodiazepine, on the stimulatory effect of hexarelin, a synthetic GHRP, on ACTH, cortisol and GH secretion in humans.

Authors:  E Arvat; B Maccagno; J Ramunni; L Di Vito; L Gianotti; F Broglio; A Benso; R Deghenghi; F Camanni; E Ghigo
Journal:  Neuroendocrinology       Date:  1998-05       Impact factor: 4.914

Review 10.  Receptors for the age of anxiety: pharmacology of the benzodiazepines.

Authors:  J F Tallman; S M Paul; P Skolnick; D W Gallager
Journal:  Science       Date:  1980-01-18       Impact factor: 47.728

View more
  12 in total

1.  Response of the hypothalamic-pituitary-adrenal axis to small dose arginine-vasopressin and daily urinary free cortisol before and after alprazolam pre-treatment differs in obesity.

Authors:  V Vicennati; L Ceroni; L Gagliardi; U Pagotto; A Gambineri; S Genghini; R Pasquali
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

2.  Alprazolam and oxazepam block the cue-induced reinstatement of extinguished cocaine seeking in rats.

Authors:  Nicholas E Goeders; David M Clampitt; Courtney Keller; Mukesh Sharma; Glenn F Guerin
Journal:  Psychopharmacology (Berl)       Date:  2008-09-17       Impact factor: 4.530

3.  Acute administration of alprazolam, a benzodiazepine activating GABA receptors, inhibits cortisol secretion in patients with subclinical but not overt Cushing's syndrome.

Authors:  Roberta Giordano; Rita Berardelli; Ioannis Karamouzis; Valentina D'Angelo; Andreea Picu; Clizia Zichi; Beatrice Fussotto; Maria Manzo; Giulio Mengozzi; Ezio Ghigo; Emanuela Arvat
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

4.  GABAergic modulation with classical benzodiazepines prevent stress-induced neuro-immune dysregulation and behavioral alterations.

Authors:  Karol Ramirez; Anzela Niraula; John F Sheridan
Journal:  Brain Behav Immun       Date:  2015-09-03       Impact factor: 7.217

5.  Interaction between Diazepam and Hippocampal Corticosterone after Acute Stress: Impact on Memory in Middle-Aged Mice.

Authors:  Daniel Béracochéa; Christophe Tronche; Mathieu Coutan; Rodolphe Dorey; Frédéric Chauveau; Christophe Piérard
Journal:  Front Behav Neurosci       Date:  2011-04-12       Impact factor: 3.558

6.  The involvement of noradrenergic mechanisms in the suppressive effects of diazepam on the hypothalamic-pituitary-adrenal axis activity in female rats.

Authors:  Dubravka Švob Štrac; Dorotea Muck-Šeler; Nela Pivac
Journal:  Croat Med J       Date:  2012-06       Impact factor: 1.351

7.  Stress responsiveness of the hypothalamic-pituitary-adrenal axis: age-related features of the vasopressinergic regulation.

Authors:  Nadezhda D Goncharova
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-12       Impact factor: 5.555

8.  Early evolution of ionotropic GABA receptors and selective regimes acting on the mammalian-specific theta and epsilon subunits.

Authors:  Christopher J Martyniuk; Stéphane Aris-Brosou; Guy Drouin; Joel Cahn; Vance L Trudeau
Journal:  PLoS One       Date:  2007-09-19       Impact factor: 3.240

9.  Effect of butorphanol, midazolam or ketamine on romifidine based sedation in horses during standing cheek tooth removal.

Authors:  Theresa Maria Müller; Klaus Hopster; Astrid Bienert-Zeit; Karl Rohn; Sabine B R Kästner
Journal:  BMC Vet Res       Date:  2017-12-06       Impact factor: 2.741

10.  Examination of Current Treatments and Symptom Management Strategies Used by Patients With Mal De Debarquement Syndrome.

Authors:  Josephine M Canceri; Rachael Brown; Shaun R Watson; Cherylea J Browne
Journal:  Front Neurol       Date:  2018-11-12       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.